Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)

Covid19 Clinical Trial

— STRUCK  

Official title:

Prospective-randomized Adaptive Study, With Active Control to Evaluate the Efficacy and Safety of Interleukin (IL)-17 Inhibitor Treatment Versus Low Doses of IL-2 Versus Indirect IL-6 Inhibitor in Hospitalized Patients With Severe Forms of COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04724629
• Other study ID #: 402422/2020-1
• Status: Completed
• Phase: Phase 3
• Start date: January 5, 2021
• Est. completion date: July 30, 2021

Study information

• Verified date: July 2022
• Source: University of Sao Paulo
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Currently, there are few approved treatments for COVID-19, antiretroviral (remdesivir) and corticoids. With about 15% of COVID-19 patients suffering from severe disease health system will be overwhelmed. Treatments approaches to inhibit viral replication (antiretroviral and extended spectrum antiviral drugs), such as Remdesivir and Hydroxychloroquine are being used. In severe cases, by CT scans investigators are able to observe that these patients seem to be dying with fibrosis and lung vasculitis. It is hypothesised that targeting vasculitis and lung inflammation secondary to the viral infection may help patients' survival (reducing mortality) and/or decrease time in mechanical ventilators. It is proposed a 4-arm trial, converted to 2 after interim analysis (60 patients for the initial phase, sample size recalculation after initial analysis and 2 arms beyond). In initial phase, IL-6 indirect inhibitor (colchicine), in first arm; IL-17 inhibitor, an innovative target never tested (at this moment) in COVID-19 severe patients, in second study arm. Both approaches (indirect IL-6 and Il-17) are related to modulation of inflammatory immune response. Finally, in third arm, IL-2 low dose. This cytokine was identified as Treg upregulation. Treg levels decrease in hepatitis C virus (HCV) associated vasculitis and increase in vasculitis resolution. In fourth arm, control group, standard of care. Initially, for the first 60 included patients, the study will comprise 4 arms (15 patients per arm, randomization ratio 1:1:1:1). An interim effectiveness and safety analysis at this point will guide the selection of one single treatment strategy (adaptative study) to be carried on after that, comparatively with the control group. The multi-site trial planned enrollment duration of 4-6 months and for each participant will be approximately 4 weeks. This trial will bring complementary data to the global effort in COVID-19 cases resolution.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: July 30, 2021
• Est. primary completion date: March 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Positive result in the quantitative real-time PCR (qPCR) test for SARS-CoV-2 in the respiratory tract;
• Pneumonia confirmed by chest imaging and

1. Respiratory rate = 24 IRPM (for adults) or

2. O2 saturation <93% or

3. No improvement in O2 saturation, despite oxygen supply or

4. Arterial hypotension; or

5. Changes in capillary filling time; or

6. Changes in the level of consciousness; or

7. Oliguria; IMPORTANT: The presence of increased respiratory rate or desaturation (items "a" and "b") are criteria for hospital admission. Items "c" to "g" are considered criteria for ICU admission Following the recommendations of The São Paulo State Health Secretariat, resolution SS-28 of 03-Mar-2020, prepared by the Hospital das Clínicas of Medical School-USP.

Exclusion Criteria:

• Age <18 years;
• Refuse to sign the Informed Consent Form;
• Patient's decision that their involvement is not in their interest;
• Severe known liver disease (eg cirrhosis, with aminotransferase levels> 5 times the reference value limit);
• Pregnancy or breastfeeding period;
• Severe bacterial infection;
• Severe diarrhea;
• Diverticulitis or intestinal perforation;
• Infection known as HIV;
• Presence of one of the following uncontrolled or unstable cardiovascular diseases:

stroke, ECG confirmed acute ischemia or myocardial infarction and / or clinically significant dysrhythmia; • Known history of gastrointestinal bleeding, uncontrolled peptic ulcer or uncontrolled duodenal ulcer;

• Known history of hemophilia or other bleeding disorders;
• History of organ transplantation, congenital immunodeficiency;

Related Conditions & MeSH terms

• COVID-19
• Covid19

Intervention

Biological:
• Ixekizumab
80 mg of IL-17 inhibitor
• Aldesleukin
1.5 million IU (low-dose) of IL-2

Drug:
• Colchicine
0.5 mg of indirect IL-6 inhibitor
• Standard of care (SOC)
Active comparator (Corticoids and antiretrovirals)

Locations

Country	Name	City	State
Brazil	Faculdade de Medicina de Ribeirão Preto - USP	Ribeirão Preto	SP
Brazil	Hospital e Maternidade Christovão da Gama	Santo André	SP

Sponsors (3)

Lead Sponsor	Collaborator
University of Sao Paulo	Conselho Nacional de Desenvolvimento Científico e Tecnológico, Science Valley Research Institute

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Correlation among the inflammatory proteins D-dimer, C- reactive protein (CRP), Lactate Dehydrogenase (LDH) Test, and ferritin with:	7 points WHO original scale; b. Time until independence from oxygen therapy; c. Need for mechanical ventilation; d. Days free of mechanical ventilation; e. Mortality	During the follow-up period (30 days (+/- 2))
Other	Changes from baseline of cytokine storm surrogate markers: white blood counts, lymphocyte counts, neutrophils counts, C-Reactive protein (CRP), ferritin (if applicable), D-dimer (if applicable)	Changes from baseline of cytokine storm surrogate markers: white blood counts, lymphocyte counts, neutrophils counts, CRP, ferritin (if applicable), D-dimer (if applicable)	at Day 0, Day 2, Day 4, Day 7, Day 14, Day 21 and Day 28 after randomization;
Other	Change in Score for Sepsis (SOFA score)		On days 7 and 14 of randomization
Other	Analysis of secondary infections		During the follow-up period (30 days (+/- 2))
Other	Qualitative and quantitative assessment of treatment- related adverse effects assessed by the Common Terminology Criteria for Adverse Event (CTCAE) version 5.0.		Within the first month
Primary	Ordinal scale of seven World Health Organization (WHO) categories of IL-17 inhibitor versus low dose IL-2 versus indirect IL-6 inhibitor (colchicine) versus standard treatment in the treatment of severe COVID-19	proportion of patients with clinical improvement, defined by an increase of two points in the ordinal scale of seven WHO categories	On the 21st day of study, since inclusion.
Secondary	Time until independence from oxygen therapy in days		During the follow-up period (30 days (+/- 2))
Secondary	Ventilator free days (in days)		During the follow-up period (30 days (+/- 2))
Secondary	Assessment of worsening pulmonary involvement, defined as the presence of one of these criteria (absence or presence)	Need to increase the inspired fraction of O2 (FIO2) to keep oxygen saturation stable or the need for mechanical ventilation; b. Increase in the number and / or extension of affected lung areas on chest computed tomography.	At some point in Day 7, Day 14 and Day 28
Secondary	In patients who needed mechanical ventilation, time to indicate mechanical ventilation	(calculated in days, from entry into the protocol until orotracheal intubation, up to 45 days)	Day 0 up to 45 days
Secondary	Duration of hospitalization, in survivors	In days	On day 28
Secondary	Analysis of in-hospital mortality		Day 0 up to 45 days
Secondary	Analysis of general mortality		During the follow-up period (30 days (+/- 2))